Intra Cellular Therapies reported $7.89M in Stock for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Stock Change
Acadia Pharmaceuticals ACAD:US $ 6.33M 0.68M
ALKERMES ALKS:US $ 155.61M 0.82M
Biocryst Pharmaceuticals BCRX:US $ 23.38M 7.23M
Biogen BIIB:US $ 1294.2M 78.8M
Bristol Myers Squibb BMY:US $ 2142M 38M
Esperion Therapeutics ESPR:US $ 29.23M 6.42M
Gilead Sciences GILD:US $ 2587M 88M
Halozyme Therapeutics HALO:US $ 97.62M 49.85M
JAZZ PHA JAZZ:US $ 861.7M 123.75M
Nektar Therapeutics NKTR:US $ 16.97M 1.59M
Neurocrine Biosciences NBIX:US $ 29.3M 0.3M
Redhill Biopharma RDHL:US $ 14.27M 0.54M
Supernus Pharmaceuticals SUPN:US $ 84.86M 3.94M
United Therapeutics UTHR:US $ 89.9M 1.7M
Vanda Pharmaceuticals VNDA:US 1.5M 206K